Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Viaud

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Ophthalmology|April 29, 2015
Author reply: To PMID 24811963Claus Cursiefen, Eric Viaud
Investigative Ophthalmology & Visual Science|February 11, 2012
Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administrationFrank Cloutier, Matthew Lawrence, Robin Goody, et al.
Ophthalmology|May 10, 2014
Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN studyClaus Cursiefen, Eric Viaud, Felix Bock, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Ophthalmology|April 29, 2015
Author reply: To PMID 24811963Claus Cursiefen, Eric Viaud
Investigative Ophthalmology & Visual Science|February 11, 2012
Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administrationFrank Cloutier, Matthew Lawrence, Robin Goody, et al.
Ophthalmology|May 10, 2014
Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN studyClaus Cursiefen, Eric Viaud, Felix Bock, et al.
Pageof 1